Search

Search Constraints

You searched for: Author/Creator Wernevik, Linda

Search Results

1. A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II. (1st October 2022)

2. AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval. Issue 11 (10th June 2022)

3. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. (22nd April 2018)

4. Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial. Issue 10 (20th August 2022)

5. Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study. Issue 2 (30th October 2019)